Despite a rapid increase in the use of anticancer immunotherapy, our understanding of the mechanisms of action and the patients’ responses remains limited. The discovery of immune inhibitory markers in the tumour microenvironment following immunotherapy should improve our understanding and might enable us to better apply combination therapies.
Refers to Gao, J. et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 23, 551-555 (2017)